Waltham, MA – April 21, 2025 — Biocytogen (HKEX: 02315), a global biotech leader in antibody discovery and preclinical services, is excited to announce the launch of its newly redesigned website: www.biocytogen.com.
More than just a visual refresh, the new website represents a strategic leap forward in Biocytogen’s vision as “the global headstream of new drugs.” The redesign is centered around creating a better experience for researchers, biotech innovators, and pharma partners worldwide.
Streamlined access to discovery platforms and assets: Visitors can easily explore Biocytogen’s therapeutic antibody development capabilities, including the proprietary RenMice® platforms and a searchable library of fully human antibody assets.
Comprehensive preclinical services, organized by need: From gene editing and humanized mouse models to pharmacology and toxicology studies, all offerings are strategically grouped to match the stages of therapeutic development — making it easier to find what matters most to your project.
Global accessibility, stronger connections: The new site is designed to bring scientists, drug developers, and partners together — making it easier to connect with our team, spark collaborations, and grow a community focused on accelerating therapeutic innovation.
With enriched content, improved user flow, and faster access to Biocytogen’s scientific platforms and services, the new website is a powerful resource for accelerating your next breakthrough.
Start exploring at www.biocytogen.com.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2024, approximately 150 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and nearly 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com/
Biocytogen Contacts
Antibody platform and assets: BD-Licensing@biocytogen.com
Preclinical models and services: info@biocytogen.com
Media: marketing@biocytogen.com
